Mycoplasma Hominis

If you have unexplained vaginal symptoms, a stubborn case of bacterial vaginosis, or you are trying to conceive and want to rule out hidden genital infections, this is one of the tests that fills a real gap. Standard sexually transmitted infection panels often check for chlamydia, gonorrhea, and trichomonas, but they routinely skip the genital mycoplasmas, leaving you and your clinician guessing about what else might be growing.

This vaginal swab looks specifically for MH (Mycoplasma hominis), a small wall-less bacterium that can quietly colonize the genital tract. Knowing whether MH is present, and what kind of company it keeps, gives you a more complete picture of your vaginal ecosystem than the typical infection screen.

What This Test Actually Detects

MH is not a hormone, protein, or human cell. It is a living bacterium with no cell wall and a tiny genome, which colonizes the urogenital tract and is mainly passed through sexual contact. A vaginal swab picks up MH cells directly from the vaginal lining, and modern assays then identify or count the bacteria using genetic amplification (PCR) or culture techniques.

Because the swab samples the vagina directly, the result reflects what is actually living on the vaginal lining, not what might be present elsewhere in the urinary tract. Head-to-head studies have found that vaginal and cervical swabs detect MH more reliably than urine samples from the same people, meaning a urine-only workup can underdetect the bacterium.

This is considered an exploratory test rather than a standard screening tool. There are no universally agreed thresholds that separate harmless colonization from active infection. The same MH-positive result can mean very different things depending on whether you have symptoms, whether bacterial vaginosis is present, and whether you are pregnant.

Why MH on a Swab Is Not Always a Diagnosis

One of the most important things to understand is that MH is not a clear-cut pathogen the way gonorrhea or trichomonas is. In a clinic-based study of 1,200 women, MH isolation rates and colony counts were broadly similar in women with and without symptoms, supporting the view that in many adults MH can behave as a commensal bug rather than an invader. The picture is not uniform across studies, though: other work has tied MH to fishy odor, a positive amine test, and elevated vaginal pH even after accounting for bacterial vaginosis, suggesting it is not always a silent bystander.

A separate study of 1,272 non-pregnant women added important nuance: MH was strongly associated with vaginal symptoms, but mainly in the context of bacterial vaginosis. Without bacterial vaginosis, an MH-positive swab in a non-pregnant woman did not track with specific genital symptoms or signs.

This is the central reconciliation for anyone confused by the test. A positive MH result is best read as a signal about your vaginal microbiome, not as a stand-alone diagnosis. The same finding can be near-meaningless in a healthy non-pregnant woman with a Lactobacillus-rich vagina and a real concern in a woman with bacterial vaginosis, fertility issues, or pregnancy.

MH and the Vaginal Microbiome

MH detection is closely tied to how the rest of your vaginal bacteria look. When the vagina is dominated by Lactobacillus crispatus, MH tends to be rare. When the community shifts toward more diverse, bacterial vaginosis–type bacteria like Gardnerella vaginalis, Atopobium vaginae, and Prevotella bivia, MH appears more often and at higher loads.

One study found a significant synergistic relationship between MH and Gardnerella vaginalis in bacterial vaginosis, suggesting the two organisms may amplify each other's presence and help trigger or sustain the condition. In a Brazilian cohort of 302 women, MH detection was also linked to higher levels of IL-1 beta, an inflammatory signaling molecule, in women with genital signs and symptoms, though the clinical significance of this inflammatory shift is still uncertain.

So a positive MH swab is often a marker of disrupted vaginal balance, even when MH itself may not be the direct cause of any symptom. That is useful information if you are trying to understand recurrent BV, unexplained irritation, or a vaginal microbiome that does not feel right.

Fertility Implications

For people actively planning a pregnancy, MH may carry more weight. A pregnancy-planning cohort of 89 women found that even low-abundance vaginal MH colonization before pregnancy was linked to a substantially lower chance of conceiving within one year compared with non-colonized women.

In a much larger cross-sectional study of infertility, MH and Ureaplasma species were commonly detected and tightly linked to each other, suggesting that genital mycoplasmas as a group deserve attention in fertility workups. A meta-analysis identified MH as a significant risk factor for female infertility (odds ratio about 1.56), while Ureaplasma urealyticum showed no consistent association.

None of this proves that MH directly causes infertility. But if you are months or years into trying to conceive without a clear explanation, knowing your MH status adds a piece of information that standard fertility labs and a routine STI panel do not provide.

Pregnancy and Adverse Outcomes

In pregnancy, MH colonization is common, with vaginal swab positivity reported in a wide range across different study populations. The clinical importance is still debated, but several lines of evidence suggest it is not always benign.

A prospective study of 200 Mongolian pregnant women found that maternal MH colonization and transmission to newborns were associated with reduced gestational age and shorter neonatal length. A systematic review and meta-analysis covering MH, Ureaplasma urealyticum, and Ureaplasma parvum found statistical associations between these genital mycoplasmas and preterm birth, premature rupture of membranes, low birth weight, and perinatal or neonatal death, though the authors note confounding and study quality issues mean causality is not settled. A more recent meta-analysis again tied cervicovaginal MH detection to preterm birth (adjusted odds ratio around 1.75) and low birth weight (odds ratio around 1.81).

A separate meta-analysis identified MH as a risk factor for female infertility and adverse pregnancy outcomes, while a cohort study of 1,349 women found no independent link between genital mycoplasma infection and spontaneous preterm birth. The pattern across studies suggests MH matters most when combined with bacterial vaginosis or other coinfections, rather than in isolation.

Cervical and HPV Connections

Persistent MH in the vaginal microbiome has been linked to persistent high-risk HPV (human papillomavirus) infection, the type of HPV most associated with cervical cancer risk. In a study of 194 women, particularly those living with HIV, persistent MH and Mycoplasma genitalium were significantly associated with persistent high-risk HPV, raising the possibility that genital mycoplasmas help create conditions that let high-risk HPV linger.

In a large Chinese cohort of nearly 9,000 reproductive-age women, MH infection and increased vaginal bacterial diversity were independently linked to a higher risk of cervical lesions among HPV-negative women. A meta-analysis tying genital mycoplasmas to cervical findings concluded that MH is associated with abnormal cervical cytology (odds ratio about 1.48), while Ureaplasma urealyticum and Mycoplasma genitalium are more strongly tied to high-risk HPV infection itself. Importantly, more recent prospective work suggests MH's cervical associations may be limited to mild cytological changes and low-grade lesions, with high-grade lesions (CIN2 and above) still driven primarily by high-risk HPV rather than MH.

Coinfections With Trichomonas and Other STIs

MH frequently shows up alongside other organisms, and these pairings can matter more than MH alone. A mini-review of the symbiosis between Trichomonas vaginalis and MH found that when these two bugs colonize together, they can drive vaginal dysbiosis and may increase the risk of HIV infection and adverse pregnancy outcomes.

Multiplex PCR panels routinely find MH alongside Ureaplasma species, Gardnerella vaginalis, Trichomonas vaginalis, and other STIs, so a single MH-positive swab is rarely the whole story. This is part of why ordering MH testing alongside a broader vaginal infection panel often gives more actionable information than testing for MH in isolation.

When Results Can Be Misleading

Several factors can blur the interpretation of an MH vaginal swab. The most important are not within-day fluctuations but the broader testing and biological context.

• Sampling site: vaginal and cervical swabs detect MH much more reliably than urine. A negative urine result does not rule out MH colonization on the vaginal lining.
• Test method: culture-based kits can miss MH compared with PCR. One culture assay had a sensitivity of about 78% and a specificity of about 99% compared with PCR, and another study found very low positive predictive value when culture was used alone in pregnant women.
• Recent intravaginal antibiotics: topical clindamycin and metronidazole used for bacterial vaginosis can lower or clear MH colonization for weeks to months, so a negative swab soon after treatment may not reflect your usual state.
• Coexisting bacterial vaginosis or other infections: an MH-positive swab in the presence of bacterial vaginosis carries a different clinical weight than the same result in a healthy, Lactobacillus-dominated vagina.

There is no published data in the human research base for this specimen on how acute illness, vigorous exercise, fasting, or recent meals shift MH levels in a 24 to 72 hour window. Standard systemic medications like statins, metformin, GLP-1 agonists (a class of drugs used for diabetes and weight), proton pump inhibitors, or thyroid medications have not been shown to change vaginal MH levels.

Tracking Your Trend

Because MH carriage shifts with your vaginal microbiome, fertility goals, and treatment history, a single swab is best seen as a snapshot rather than a verdict. If your first result is positive and you are symptomatic or trying to conceive, retesting after any targeted treatment or microbiome-focused intervention helps confirm whether MH has cleared or persists.

There is no clinical guideline that specifies how often to retest a vaginal MH swab. As an empirical, non-guideline-endorsed approach for proactive people, a reasonable cadence is a baseline test now, a follow-up 3 to 6 months later if you are making changes (treating BV, addressing fertility, supporting Lactobacillus dominance), and at least annual retesting if you have ongoing concerns or recurrent symptoms. Retesting becomes especially relevant if you start a new sexual relationship, develop unexplained vaginal symptoms, or are planning pregnancy.

Tracking also matters because spontaneous clearance can happen for genital mycoplasmas. In a prospective cohort of women undergoing pregnancy termination, the related organism Mycoplasma genitalium cleared on its own in about 46% of cases, with lower bacterial load at the start being the main factor. MH itself has not been studied as systematically for clearance, and because MH and Mycoplasma genitalium are biologically distinct organisms, this M. genitalium clearance rate cannot be assumed to apply to MH directly. The broader takeaway is simply that a single positive swab is not necessarily permanent.

What to Do With an Unexpected Result

If your MH swab comes back positive, the decision pathway depends on context, not on a single threshold.

• If you have symptoms or bacterial vaginosis: an MH-positive result is most clinically meaningful here. Pair it with a full vaginal panel that covers Gardnerella, Trichomonas, Ureaplasma, Mycoplasma genitalium, Candida, and standard STIs. Treatment decisions are typically guided by an infectious disease specialist or gynecologist who can weigh resistance patterns.
• If you are trying to conceive: discuss the result with a reproductive endocrinologist or fertility-focused gynecologist, especially if you have unexplained infertility or prior pregnancy loss. Companion testing for Ureaplasma species and Mycoplasma genitalium is usually warranted.
• If you are pregnant or planning pregnancy: maternal-fetal medicine input is appropriate, particularly if you have a history of preterm birth, premature rupture of membranes, or recurrent miscarriage. Resistance profiling matters because high rates of resistance to erythromycin and tetracycline have been reported in genital mycoplasmas from pregnant women.
• If you are asymptomatic with a healthy microbiome and no fertility concerns: an MH-positive result alone may not require action. European clinical guidance specifically cautions against routine screening or treatment of asymptomatic genital mycoplasma colonization, given uncertain benefits and rising antimicrobial resistance.

Across all of these scenarios, a single MH-positive swab rarely warrants drastic action on its own. The most useful next steps are confirming the result, understanding the broader microbial context, and matching treatment intensity to clinical need.